Induced resistance to ifosfamide in osteosarcoma cells suggests a more aggressive tumor profile.

ABSTRACT:

Aims

Osteosarcoma (OS) is the most common primary malignant bone sarcoma among children and adolescents. Treatment is based on neo-adjuvant and adjuvant chemotherapy, using the standard drugs cisplatin, methotrexate, doxorubicin, and ifosfamide (IFO). Due to the high capacity of tumor resistance, the current work aimed to analyze genes related to cycle control and cell differentiation in OS cells sensitive to and with induced resistance to IFO. This was to assess whether the differentiated expression of these genes may affect resistance to the drug IFO used in OS treatment, and thus establish possible biomarkers of disease progression.

Materials and methods

In this work, the treatment-sensitive OS U2OS lineage was used, and the same lineage was submitted to the process of in

SUBMITTER: de Oliveira Rodrigues MT 

PROVIDER: S-EPMC9535421 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature